International Reporting Mechanism for Unethical Germline Gene Editing Experiments Is Needed
By G. Owen Schaefer, Markus K. Labude, Yujia Zhu, Roger Sik-Yin Foo, Vicki Xafis,
Trends in Biotechnology
| 11. 04. 2020
The 2018 revelation of the birth of the first babies whose DNA had been edited shocked the world and was met almost instantly with condemnation from scientists, ethicists, and policymakers around the world [1] (Box 1). The news was not a shock to quite everyone, however. A recent article reveals that a large number of individuals around the world knew about the experiment, in one form or another, before the news broke internationally [2]. He Jiankui, who led the experiment, had built up an international network of collaborators for several of his biotechnology ventures and at various stages communicated progress of his experiment to international colleagues. Some now say they tried to discourage him, but none made known the ongoing experiment to the broader international community.
In this article, we argue that revealing such activities is in line with scientists’ responsibilities to uphold the integrity and trustworthiness of the scientific enterprise. However, the international context complicates the situation; it is not clear whom individuals who knew about the experiment should have approached. To fill...
Related Articles
By David Jensen, The California Stem Cell Report | 03.26.2026
SACRAMENTO, Ca. -- California’s $12 billion stem cell and gene therapy program scored a historic first today, announcing that it had for the first time helped to finance a revolutionary treatment that will now be available to the general public...
Cathy Tie seems to be good at starting businesses but not so dedicated to maintaining them. CGS, like many others, first heard of her thanks to Caiwei Chen and Antonio Regalado in MIT Technology Review, May 2025, as the partner (perhaps bride) of the notorious Chinese scientist He Jiankui, described in the headline as “China’s Frankenstein.” He prefers “Chinese Darwin.” She ran his Twitter account for a while, contributing such gems as:
Get in luddite, we’re going gene editing...
By Laura DeFrancesco, Nature Biotechnology | 03.17.2026
The first gene editors designed to fix genetic lesions in mutation-agnostic ways are poised to enter the clinic. Tessera Therapeutics and Alltrna, two Flagship Pioneering-funded companies, are gearing up to test novel genetic medicines in humans. Tessera received regulatory clearance...
By Darren Incorvaia, Fierce Biotech | 03.11.2026
A new method for safely inserting large chunks of DNA into genomes has now measured up in mice, potentially paving the way for the next generation of gene editing medicines.
The approach, which is described in a Nature paper...